Similar articles

• Epstein-Barr antibodies in suspected nasopharyngeal carcinoma.

  Ho HC, Kwan HC, Wu P, Chan SK, Ng MH, Saw D. Ho HC, et al. Lancet. 1978 Nov 18;2(8099):1094-5. doi: 10.1016/s0140-6736(78)91825-1. Lancet. 1978. PMID: 82106 No abstract available.
• Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma.

  Ho HC, Kwan HC, Ng MH, de The G. Ho HC, et al. Lancet. 1978 Feb 25;1(8061):436. doi: 10.1016/s0140-6736(78)91220-5. Lancet. 1978. PMID: 75457 No abstract available.
• The genetic and antigenic basis for the IgA antibody response to Epstein-Barr viral capsid antigen.

  Ng MH, Ho HC, Kwan HC. Ng MH, et al. IARC Sci Publ (1971). 1978;(20):449-58. IARC Sci Publ (1971). 1978. PMID: 215527 No abstract available.
• [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].

  Mazeron MC. Mazeron MC. Bull Cancer Radiother. 1996;83(1):3-7. Bull Cancer Radiother. 1996. PMID: 8679277 Review. French.
• Seroepidemiological studies on nasopharyngeal carcinoma in China.

  Zeng Y. Zeng Y. Adv Cancer Res. 1985;44:121-38. doi: 10.1016/s0065-230x(08)60027-5. Adv Cancer Res. 1985. PMID: 2994402 Review. No abstract available.